Section Arrow
GILD.NASDAQ
- Gilead Sciences
Quotes are at least 15-min delayed:2024/10/31 18:41 EDT
Last
 88.81
+0.52 (+0.59%)
Day High 
89.28 
Prev. Close
88.29 
1-M High
89.74 
Volume 
5.89M 
Bid
88.2
Ask
88.77
Day Low
87.74 
Open
87.94 
1-M Low
82.82 
Market Cap 
109.92B 
Currency USD 
P/E 107.96 
%Yield 3.45 
10-SMA 87.87 
20-SMA 86.52 
50-SMA 83.2 
52-W High 89.74 
52-W Low 62.07 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.82/7.20
Enterprise Value
133.11B
Balance Sheet
Book Value Per Share
14.68
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
132.30M
Operating Revenue Per Share
22.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PFEPfizer28.3-0.22-0.77%76.86PE
BMYBristol-Myers Squibb Co55.77+3.11+5.91%11.67PE
MRKMerck & Co102.32-2.51-2.39%19.39PE
GSKGSK plc36.76-0.25-0.68%12.75PE
ABBVABBVIE203.87+2.37+1.18%67.54PE
Quotes are at least 15-min delayed:2024/10/31 18:41 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.